University of Texas: Combined Therapy May Improve Clinical Responses for Endometrial, Colorectal and Gastric Tumors
February 28, 2020
February 28, 2020
HOUSTON, Texas, Feb. 28 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
- Enzyme inhibitor with anti-PD1 checkpoint blockade boosted efficacy over either treatment alone
* * *
A study at The University of Texas MD Anderson Cancer Center discovered a novel therapeutic vulnerability for patients who have tumors caused by a genetic misfire in the DNA mismatch repair (MMR) pathway . . .
* * *
- Enzyme inhibitor with anti-PD1 checkpoint blockade boosted efficacy over either treatment alone
* * *
A study at The University of Texas MD Anderson Cancer Center discovered a novel therapeutic vulnerability for patients who have tumors caused by a genetic misfire in the DNA mismatch repair (MMR) pathway . . .